Malaysia Atherosclerosis Therapeutics Market Analysis

Malaysia Atherosclerosis Therapeutics Market Executive Summary

Malaysia Atherosclerosis Therapeutics Market was valued at $5 Mn in 2022 and is estimated to reach $7 Mn in 2030, exhibiting a CAGR of 5.9% during the forecast period.

Plaque, a sticky substance made of calcium, fat, cholesterol, and other ingredients, builds up inside the artery walls as a result of atherosclerosis. Because of this accumulation, there is a higher chance of developing severe conditions, including heart attacks and strokes, which constrict or clog blood vessels. Atherosclerosis can be caused by a variety of factors, such as high blood pressure, high cholesterol, diabetes, obesity, smoking, a family history of heart disease, inactivity, and an unhealthful diet. Several drugs, such as beta-blockers, aspirin, and statins, have shown potential in preventing or reducing the advancement of atherosclerosis.

In Malaysia, 1,869 people out of 100,000 are considered to have high-risk atherosclerotic cardiovascular disease (ASCVD); this group includes people who have a history of certain cardiovascular events as well as people who have multiple risk factors such as diabetes, hypertension, and dyslipidaemia. In individuals 18 years of age and older, the estimated prevalence of hypertension is 28.1%, while the prevalence of diabetes is 18.2% in the same age range. Dyslipidaemia, a condition marked by elevated cholesterol levels, affects about 30–40% of adult Malaysians. Atherosclerosis prevalence tends to increase with age, affecting more individuals in older age groups, and men generally exhibit a higher prevalence than women, particularly at younger ages, though the gap narrows with age, and women eventually catch up or surpass men in prevalence after menopause.

Initiation of a Phase 3 clinical trial in patients with established atherosclerotic cardiovascular disease (ASCVD) to evaluate the effect of Inclera (fenofibrate) on the risk of major adverse cardiovascular events (MACE). This important trial aims to shed light on Inclera's possible advantages and safety profile for this particular patient population. To better understand the long-term safety and efficacy of Crestor (rosuvastatin) in people with atherosclerotic disease, AstraZeneca and Eisai are working together to perform a Phase 4 trial in Malaysia. To obtain a deeper understanding of the long-term therapeutic benefits and safety issues related to Crestor use, a thorough examination is necessary.

Market Dynamics

Market Growth Drivers

Aging Population: The increasing prevalence of an aging population in Malaysia, characterized by a rising number of individuals aged 65 and above, is anticipated to nearly double from 6.4 million in 2020 to 14.7 million by 2050. This demographic shift amplifies the demand for atherosclerosis treatment drugs, as the elderly population is inherently at a heightened risk of developing atherosclerosis and related complications, thereby acting as a significant market growth driver in Malaysia.

Rising Prevalence of Risk Factors: With a substantial portion of the Malaysian population exhibiting high-risk Atherosclerotic Cardiovascular Disease and an escalating prevalence of hypertension, diabetes, and dyslipidemia driven by factors such as unhealthy lifestyles and urbanization, the expanding demand for medications to address these conditions acts as a key driver for market growth in the atherosclerosis treatment drug sector in Malaysia.

Advancements in Drug Development: To address the needs of a growing patient base and a variety of demands, pharmaceutical companies' persistent efforts to develop novel atherosclerosis drugs tailored to various pathways and patient needs are expected to accelerate market expansion in Malaysia.

Market Restraints

Affordability: A large fraction of the population has barriers to accessibility because of the high cost of modern atherosclerosis treatment drugs, as well as expenses from imported medications due to import tariffs and exchange rate changes. Even with the growing availability of generic medications, there are still gaps in affordability that mostly affect people with low incomes and those living in remote regions. This affordability issue affects a significant portion of the population that has financial difficulties and impedes the wider acceptance and accessibility of atherosclerosis drug treatment in Malaysia.

Compliance and Adherence Issues: The prolonged use of drugs in atherosclerosis treatment poses challenges such as adverse effects, forgetfulness, and low motivation for some patients. Managing numerous prescriptions for different medical conditions makes adherence problems worse, which could limit the commercial potential of atherosclerosis treatment options because of difficulties with patient compliance.

Healthcare infrastructure limitations: Inequitable access to healthcare services, particularly in remote regions, may impede prompt identification and treatment of atherosclerosis. A lack of knowledge about risk factors and financial difficulties brought on by inadequate insurance coverage for chronic conditions like atherosclerosis might cause delays. These challenges in Malaysia's healthcare infrastructure impact patient awareness, accessibility, and financial support, posing obstacles to effective atherosclerosis management.

Healthcare Policies and Regulatory Landscape

The National Pharmaceutical Regulating Agency (NPRA), which is the principal regulating body for treatment pharmaceuticals in Malaysia, operates under the Ministry of Health. The NPRA guarantees the quality, safety, and efficacy of pharmaceutical products through overseeing medication registration, approval, and post-market surveillance. To ensure constant quality in the production of pharmaceuticals, adherence to GMP guidelines is strictly enforced. The Pharmacy Practice and Poisons Act of 1952 governs the sale and distribution of therapeutic drugs, among other pharmacy-related operations. The safety and effectiveness of medicines that have been approved are evaluated by continuous post-market surveillance. Important medications that must adhere to certain standards are listed on the National Essential Medicines List. Furthermore, Malaysia investigates the application of Health Technology Assessment to assess the effects of novel health technologies, such as medications.

Competitive Landscape

Key Players

• Novartis
• Pfizer
• AstraZeneca
• Eisai
• Merck Sharp & Dohme
• Sanofi
• Bayer
• Abbott
• Johnson & Johnson
• Roche